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Abstract
Background: Since tacrolimus ointment was approved by the U.S. Food and Drug Administration
(FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30
additional countries, including numerous European Union member nations. Moreover, in the
current clinical routine the use of this drug is no longer restricted to the approved indication, but
has been extended to a wide variety of inflammatory skin diseases including some with the potential
of malignant transformation. So far, the side-effects reported from the topical use of tacrolimus
have been relatively minor (e.g. burning, pruritus, erythema). Recently, however, the FDA reviewed
the safety of topical tacrolimus, which resulted in a warning that the use of calcineurin inhibitors
may be associated with an increased risk of cancer.
Case presentation: Oral lichen planus (OLP) was diagnosed in a 56-year-old women in February
1999. After several ineffective local and systemic therapeutic measures an off-label treatment of this
recalcitrant condition using Tacrolimus 0.1% ointment was initiated in May 2002. After a few weeks
of treatment most of the lesions ameliorated, with the exception of the plaques on the sides of the
tongue. Nevertheless, the patient became free of symptoms which, however, reoccurred once
tacrolimus was weaned, as a consequence treatment was maintained. In April 2005, the plaques on
the left side of the tongue appeared increasingly compact and a biopsy specimen confirmed the
suspected diagnosis of an oral squamous cell carcinoma.
Conclusion:  The suspected causal relationship between topical use of tacrolimus and the
development of a squamous cell carcinoma prompted us to test the notion that the carcinogenicity
of tacrolimus may go beyond mere immune suppression. To this end, tacrolimus has been shown
to have an impact on cancer signalling pathways such as the MAPK and the p53 pathway. In the
given case, we were able to demonstrate that these pathways had also been altered subsequent to
tacrolimus therapy.
Background
Tacrolimus is the generic name for the macrolide immu-
nosuppressant previously known by its experimental
name FK506 [1]. Tacrolimus was first discovered while
screening for antibacterial activity of a multitude of com-
pounds. This macrolide is produced by Streptomyces tsu-
kabaensis, a bacterium found in the soil near Tsukuba,
Japan. The mechanism of action of tacrolimus is closely
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related to that of cyclosporine. However, while tacrolimus
binds tightly to the cellular protein named FKBP (FK506-
binding protein) 12, cyclosporine binds cyclophilin. The
target of either drug/intracellular receptor complex is a
calcium-activated phosphatase called calcineurin, which
is required for many functions in a variety of tissues: learn-
ing and memory, renal function, and immune responses.
The selective sensitivity of immune function to these
drugs has two reasons: 1. the low level of expression of cal-
cineurin in lymphocytes relative to cells in other tissues; 2.
an absolute requirement for calcineurin in immune acti-
vation. During antigen specific T-cell activation intracellu-
lar calcium is released and calcineurin is activated to
dephosphorylate its target proteins including the tran-
scription factor NFAT (nuclear factor of activated T cells).
Upon dephosphorylation, NFAT translocates to the
nucleus, where it binds its nuclear counterpart to form an
active transcription factor inducing the production of sev-
eral cytokines mandatory for initiating an immune
response. Hence, calcineurin inhibitors interfere with
antigen specific T-cell activation. Furthermore, tacrolimus
affects the function of mast cells, basophile leucocytes and
Langerhans cells. These characteristics explain the great
interest to apply tacrolimus topically on inflamed skin,
particularly since it was the first new topical immune sup-
pressant since the introduction of steroids. The first suc-
cessful use of topical tacrolimus in patients with atopic
dermatitis was reported by Nakagawa et al. in 1994 and
already 6 years later the U.S. Food and Drug Administra-
tion (FDA) approved tacrolimus ointment as a promising
treatment for atopic dermatitis [2,3]. Additionally, tac-
rolimus was investigated for a wide variety of inflamma-
tory skin diseases beyond atopic dermatitis; particularly
for conditions recalcitrant to other forms of therapy.
Lichen planus is a relatively common disorder, estimated
to affect 0.5% to 2.0% of the general population. It is a
chronic, inflammatory disease that affects mucosal and
cutaneous tissues. Oral lichen planus (OLP) occurs more
frequently than the cutaneous form, and while cutaneous
lesions in the majority of patients are self-limiting and
mainly cause pruritus, oral lesions are chronic, rarely
undergo spontaneous remission, and are a potential
source of significant morbidity [4]. Several clinical forms
of OLP have been described, but in general three types of
lesions can be distinguished: reticular, including white
lines, plaques and papules; atrophic or erythematous; and
erosive, including ulcerations and bullae. The classic his-
topathologic features of OLP include liquefaction of the
basal cell layer accompanied by apoptosis of the keratino-
cytes and a dense band-like lymphocytic infiltrate at the
interface between the epithelium and the connective tis-
sue. In addition, focal areas of hyperkeratinized epithe-
lium, which give rise to the clinically apparent Wickham's
striae, and occasional areas of atrophic epithelium where
the rete ridges may be shortened and pointed result in a
saw tooth appearance. Finally, eosinophilic colloid bod-
ies representing degenerated keratinocytes, in the lower
half of the surface epithelium are typical. Whereas reticu-
lar lesions are generally asymptomatic and often discov-
ered incidentally during an oral examination,
erythematous and erosive lesions frequently result in dis-
comfort, causing patients to seek care. Unfortunately, oral
lesions are difficult to palliate. Indeed, meta-analyses pro-
vided little evidence for the superiority of any assessed
interventions over placebo for palliation of symptomatic
OLP [4]. Therefore it is important that several recent
reports suggest the long-term efficacy and safety of topical
tacrolimus for the treatment of OLP in more than 100
patients [5-9].
Case presentation
A 59-year-old women was seen in February 1999, present-
ing interlacing white keratotic lines with an erythematous
border located bilaterally on the buccal mucosa and the
palate. Additional lesions were found on both sides of the
tongue; the latter were of plaque-like form and resembled
leukoplakia. Particularly the plaque-like lesions were
associated with a moderate burning sensation. Upon fur-
ther clinical examination, additional genital lichen planus
lesions involving the introitus vaginae were detected. Two
biopsy specimens were taken, which established the diag-
nosis of OLP. Tests for hepatitis B and C were negative;
laboratory analyses revealed no pathological findings.
Mycology swabs did not show significant growth of cand-
ida albicans. However, the patient received sympathicolyt-
ics for anti-hypertensive therapy. In the following, the
sympathicolytics were substituted by Ca-antagonists.
After contra-indicating conditions were ruled out, the
patient received systemic dapsone therapy in combina-
tion with vitamine E. Locally, mometasone furoate mono-
hydrate cream was applied twice daily. These measures
largely palliated the symptoms and the clinical aspect was
improved, but lesions never cleared completely. After
approximately one year without any further improve-
ment, dapsone therapy was discontinued and new biopsy
specimens were taken. The histological workup, however,
was not specific, but a bullous autoimmune disease could
be excluded. In July 2001, systemic acitretin at 0.5 mg/kg
body weight was started, but stopped within 6 weeks due
to elevated serum lipids. Subsequent biopsy specimens of
the genital and oral mucosa were consistent with lichen
planus. Due to severe symptoms interfering with normal
masticatory function, systemic high dose dexamethasone
(100 mg on three consecutive days every 4 weeks) was
administered three times, unfortunately without any suc-
cess. As a consequence, in May 2002 an off-label treat-
ment of the recalcitrant OLP was initiated. Tacrolimus
0.1% ointment (Protopic® 0.1%) was applied twice daily.
Substantial pain relief was reported after a few weeks ofBMC Cancer 2006, 6:7 http://www.biomedcentral.com/1471-2407/6/7
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Macroscopic, microscopic and immune histological appearance of an oral lichen planus and a subsequently arising squamous cell  carcinoma Figure 1
Macroscopic, microscopic and immune histological appearance of an oral lichen planus and a subsequently 
arising squamous cell carcinoma. Macroscopic (A) and microscopic (B) picture of the squamous cells carcinoma. p53 
expression (C to E, single positive cells are indicated by arrows), Erk 1/2 phosphorylation (F to H, increased expression is indi-
cated by closed triangles) and Bax expression (I to K, reduced expression is indicated by open triangles) in mucosa before (C, 
F, I) and after (D, G, J) tacrolimus treatment, as well as in the arising squamous cell carcinoma (E, H, K); magnification: A 5×, C 
to K 20×. All lesions were obtained by surgical excision, fixed in formalin and embedded in paraffin. Five µm sections of tumor 
lesions were fixed in acetone and air dried for 30 min. Slides were incubated for 30 min with the indicated specific primary anti-
bodies (anti-p53 [clone D07] and anti-Bax [polyclonal], DAKO, Hamburg, Germany; anti-pErk 1/2 [clone E10], Cell Signalling, 
BioLabs New England, Frankfurt, Germany) at predetermined dilutions ranging from 1:200 to 1:800.
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treatment and most of the lesions ameliorated, with the
exception of the plaques on the sides of the tongue. After
reduction of the frequency of treatment, a recurrence was
observed with an increasing number of ulcerated lesions.
Consequently, tacrolimus 0.1% was again administered
twice daily. In October 2003 an additional biopsy speci-
men was taken of the ulcerated plaque on the side of the
tongue confirming the diagnosis of OLP without evidence
of neoplastic transformation. Albeit the OLP did not
resolve by treatment with tacrolimus, the patient
remained free of symptoms. Hence, the therapy was main-
tained; however, it was attempted to decrease the fre-
quency of tacrolimus administration. In April 2005, the
plaques on the left side of the tongue appeared increas-
ingly compact and a biopsy specimen confirmed the sus-
pected diagnosis of an oral squamous cell carcinoma
(Figure 1A and 1B). After exclusion of systemic metas-
tases, a combination of radiation and chemotherapy was
initiated to be followed by surgery.
The pre-malignant potential of OLP has been a controver-
sial issue for the past several decades. Indeed, the reported
transformation rates vary from 0 to 9% [4,10,11]. Some of
the controversy can be attributed to the fact that several
studies have focused on the development of oral cancer in
cohorts of patients with OLP diagnosed on the basis of
different criteria and followed for various periods of time.
Despite these differences, the majority of studies have
reported a rate of malignant transformation of OLP
between 0.5 and 2% over a five year period. Unfortu-
nately, no obvious specific clinical features unequivocally
predict the potential for cancer development. In this
respect it should be noted, that the notion that ulcerative/
erosive OLP lesions are more prone to develop into cancer
Hypothetical effects of tacrolimus in keratinocytes promoting oncogenic transformation Figure 2
Hypothetical effects of tacrolimus in keratinocytes promoting oncogenic transformation.
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could not be confirmed. A recent meta-analysis revealed
that the different types of OLP developing oral cancer
have a rather equal distribution: reticular 33%, plaque
29%, atrophic 13%, and ulcerative/erosive 25% [11]. It
has also been proposed, that otherwise benign appearing
lesions showing an over-expression of p53 in some of the
cells implies the expression of mutated p53 which may be
an indicator of potential malignant development. Nota-
bly, retrospective analysis of the biopsy specimens
revealed such accumulation of p53 over-expressing cells
in small clusters (Figure 1C and 1D).
The risk of using tacrolimus topically with respect to car-
cinogenesis has been of some concern. The reason for this
is the fact that systemic long-term treatment with tac-
rolimus in organ transplant recipients increases the inci-
dence of malignant tumours, particularly squamous cell
carcinoma [12]. Recently, there was a first report of the
development of a squamous cell carcinoma of the penis
after topical use of tacrolimus [13]. In March 2005 the
FDA has issued a public health advisory to inform health-
care professionals and patients about a potential cancer
risk from the use of tacrolimus which was based on ani-
mal studies and case reports in a small number of patients
[14]. Causative associations are uncertain, but several
patients in whom cancer developed after drug use have
been reported. For tacrolimus, 19 cases of cancer were
reported, involving 16 adults and 3 children under the age
of 16. The cancers were diagnosed 21–790 days after the
start of therapy. Nine cases involved lymphomas, and 10
involved skin tumours. The majority of the skin tumours
occurred at the site of the drug application. Tumour types
included squamous cell carcinoma, cutaneous sarcoma
and malignant melanoma. The mechanism is thought to
be an inhibition of immune competent cells, which nor-
mally survey and prevent malignant and pre-malignant
cells from developing into malignant tumours.
It was shown that tacrolimus accelerates carcinogenesis in
mouse skin when applied topically after the skin had been
pre-treated with a tumour initiator (DMBA) [15]. Because
of a reduction in the CD4/CD8 ratio found in the lymph
nodes in tacrolimus-treated mice, the authors concluded
that the immunosuppressive effect of the drug was
responsible for its effect in promoting tumourigenesis.
This notion was further substantiated by the finding that
the concentration of tacrolimus in the draining lymph
node was as high as lymph nodes of animals receiving
oral tacrolimus, despite the fact that the serum concentra-
tion of tacrolimus in topically treated mice was 50- to
100-fold lower [16]. It should be further noted, that
despite of an augmentation of apoptosis in T-cells, tac-
rolimus was also shown to inhibit apoptosis in non-lym-
phoid cells [17-20]. Moreover, an influence on proteins of
some of the most significant cancer signalling pathways
(e.g. Erk and p53) has been demonstrated (Figure 2) [19-
22]. Consequently, the carcinogenic potential of tac-
rolimus may be also due to an direct effect, promoting the
transformation of initiated cells.
Treatment with tacrolimus leads to Erk activation in neu-
ronal cells and inhibits the induction of p53 following an
apoptotic stimulus in several cell systems [19-22]. In the
present case, we actually observed an increased presence
of phosphorylated Erk 1/2 within the mucosal epithelium
after tacrolimus therapy (Figure 1F and 1G). Moreover,
strong phosphoErk signals were obvious in the cells of the
tongue carcinoma (Figure 1H). Since the expression levels
of p53 are difficult to interpret, as in many tumours p53
accumulates as an inactive mutated protein, we also ana-
lysed the expression level of Bax (Figure 1E and 1I to 1K).
Bax is a proapoptotic member of the Bcl-2 family and its
transcription is directly regulated by p53; hence it may
serve as a read out of p53 function. Moreover, it was
already reported that tacrolimus prevented an increase in
the Bax/Bcl-2 ratio following an apoptotic stimulus in
U251 cells, while others found a reduction in mitochon-
drial Bax with the overall expression level remaining
unchanged [19,20]. Strikingly, we observed a reduction of
Bax expression in epithelial cells in some areas of tac-
rolimus treated mucosa and this reduction was also
present in the carcinoma cells (Figure 1I to 1K). It should
be further noted, that an even more direct link between
tacrolimus and Bcl-2 family proteins results of the finding
that the tacrolimus-binding protein FKBP 38 blocks apop-
tosis, binds to Bcl-2 and targets Bcl-2 to the mitochondria
[17].
Conclusion
Taken together, previous reports and our observation sug-
gest that a carcinogenic potential of tacrolimus might also
be mediated via direct effects thereby promoting onco-
genic transformation of initiated cells. We are fully aware
that this is a rather hypothetical scenario and we sincerely
hope that the future will prove it wrong. However, it may
take human studies of ten years or longer to determine if
use of tacrolimus is linked to cancer [23,24]. In the mean-
time, we hope that this report may raise some concern
about the potential carcinogenic effect of tacrolimus and
similar compounds which goes beyond indirect mecha-
nisms caused by immune suppression. Moreover, it
should be kept in mind that innovative and effective drugs
which interfere with intracellular signalling are likely to
have more impact on the cell than initially anticipated.
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